Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Antitumor Effects of a Recombinant Baculovirus Displaying Anti-Her2 Scfv Expressing Apoptin in Her2 Positive Sk-Br-3 Breast Cancer Cells Publisher



Meysami P1 ; Rezaei F1 ; Marashi SM1 ; Amiri MM2 ; Bakker E3 ; Mokhtariazad T1
Authors

Source: Future Virology Published:2019


Abstract

Aim: Since HER2 targeted therapies have shown clinical benefit in breast cancer, in the present study recombinant baculovirus (BV) displaying anti-HER2 single-chain variable domain fragment (scFv) expressing Apoptin was generated. Methods: The binding specificity and surface display of anti-HER2 scFv were evaluated using enzyme-linked immunosorbent assay (ELISA) and electron microscopy, respectively. The targeting properties and cytotoxic effect on breast cancer cells determined by fluorescence microscopy and MTT assays. Results: The results demonstrated that recombinant BV could specifically bind to HER2-overexpressing SK-BR-3 cells but not to the HER2 negative MCF-7 cells and reduced the viability of SK-BR-3 cells by expressing Apoptin. Conclusion: These results suggest that the antitumor effect of Apoptin in combination with HER2 targeting of this recombinant BV makes it a promising vector in targeted cancer therapy. © 2019 Future Medicine Ltd.
Related Docs
View other Related Docs
1. The Role of Endogenous Retroviruses-K in Human Cancer, Reviews in Medical Virology (2020)
2. Production of Human Single-Chain Fragment Antibody (Scfv) Against Human Epidermal Growth Factor Receptor-2 (Her-2) by Phage Display Technology, In Vitro Cellular and Developmental Biology - Animal (2018)
3. Reduced Tumor Volume and Increased Necrosis of Human Breast Tumor Xenograft in Mice Pretreated by a Cocktail of Three Specific Anti-Her2 Scfvs, Current Protein and Peptide Science (2024)
Experts (# of related papers)
View all Related Experts
Fazel Shokri (8)
Mohammad Mehdi Amiri (6)
Other Related Docs
4. Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression, International Immunopharmacology (2023)
5. Establishment of a Murine Model of Breast Cancer Expressing Human Epidermal Growth Factor Receptor 2 (4T1‑Her2), Journal of Cancer Research and Therapeutics (2024)
6. Recent Progress in Immunotherapy of Breast Cancer Targeting the Human Epidermal Growth Factor Receptor 2 (Her2), Journal of Oncology Pharmacy Practice (2021)
7. Antibody Response to Her2 Extracellular Domain and Subdomains in Mouse Following Dna Immunization, Tumor Biology (2016)
8. In Silico Evaluation of Two Targeted Chimeric Proteins Based on Bacterial Toxins for Breast Cancer Therapy, International Journal of Cancer Management (2019)
9. Differential Effects of Inhibitory and Stimulatory Anti-Her2 Monoclonal Antibodies on Akt/Erk Signaling Pathways, Asian Pacific Journal of Cancer Prevention (2018)
10. Improvement of Cytotoxicity and Necrosis Activity of Ganoderic Acid a Through the Development of Pmbn-A.Her2-Ga As a Targeted Nano System, RSC Advances (2022)
11. Antibody Response to Human Extracellular Her2 Subdomain Proteins in Mice, Iranian Journal of Immunology (2017)
12. Evaluation of Apoptosis Induction by Newcastle Disease Virus Lasota Strain in Human Breast Carcinoma Cells; [Evaluation De L'induction De L'apoptose Par La Souche Lasota Du Virus De La Maladie De Newcastle Dans Les Cellules De Carcinome Du Sein Humain], Archives of Razi Institute (2020)
13. Radiolabeled Her2-Targeted Molecular Probes in Breast Cancer Imaging: Current Knowledge and Future Prospective, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
14. Human Cytomegalovirus and Epstein-Barr Virus Infections in Breast Cancer: A Molecular Study on Iranian Women, Breast Disease (2021)
15. A Novel Anti-Her2 Bispecific Antibody With Potent Tumor Inhibitory Effects in Vitro and in Vivo, Frontiers in Immunology (2021)
16. Bacmam Virus-Based Surface Display for Hcv E2 Glycoprotein Induces Strong Cross-Neutralizing Antibodies and Cellular Immune Responses in Vaccinated Mice, Infectious Agents and Cancer (2021)
17. A Case Report of the Sustained and Rapid Response of Bevacizumab in a Tp53-Positive Breast Cancer and Liver Metastatic Patient Through Personalized Medicine, Frontiers in Oncology (2022)
18. Evaluation of the Anti-Tumor Effects of an Anti-Human Epidermal Growth Factor Receptor 2 (Her2) Monoclonal Antibody in Combination With Cd11b+/Gr-1+ Myeloid Cells Depletion Using a Recombinant Peptibody in 4 T1-Her2 Tumor Model, International Immunopharmacology (2023)
19. Polyclonal Antibody Against Different Extracellular Subdomains of Her2 Induces Tumor Growth Inhibition in Vitro, Iranian Journal of Immunology (2017)
20. Potent Synergistic Anti-Tumor Activity of a Novel Humanized Anti-Her2 Antibody Hersintuzumab in Combination With Trastuzumab in Xenograft Models, Investigational New Drugs (2021)